Brief: Guardant Health Q4 Adjusted EPS USD -0.5 Vs. IBES Estimate USD -0.7
19/02/2026 21:05
Feb 19 (Reuters) - Guardant Health Q4 adjusted net income USD -63.8 million vs. IBES estimate USD -93.2 million. Q4 adjusted EBITDA USD -64.9 million vs. IBES estimate USD -49.9 million Q4 EPS USD -1 outlook FY revenue USD 1,250-1,280 million
Recent news on Guardant Health
See all newsBrief: Guardant Health Announces Approval In Europe Of Guardant360® Cdx
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
US Health Secretary Kennedy Jr. adds eight new members to key health committee (updated)
Brief: US FDA Grants Accelerated Approval To Etcamah For Advanced Breast Cancer With ESR1 Mutation
Brief: Guardant Health To Appeal Federal District Court Judgment